Role of the vasodilator peptide angiotensin-(1-7) in cardiovascular drug therapy

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 125-137

  Schindler, Christoph ^a   Bramlage, Peter ^a   Kirch, Wilhelm ^a   Ferrario, Carlos M ^b  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin (1 7); Cardiovascular drug therapy; Renin angiotensin system

Indexed keywords

A 779; ALISKIREN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSIN[1-7]; ANGIOTENSIN[1-7] AGONIST; ANGIOTENSIN[1-7] ANTAGONIST; AVE 0991; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENALAPRILAT; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR AFFECTING AGENT; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; OMAPATRILAT; PEPTIDE; RENIN INHIBITOR; UNCLASSIFIED DRUG; VASODILATOR AGENT; VASOPEPTIDASE INHIBITOR;

BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CLINICAL STUDY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; ENZYME MECHANISM; EXPERIMENTAL STUDY; HUMAN; KIDNEY FUNCTION; MONOTHERAPY; NONHUMAN; REGULATORY MECHANISM; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANGIOTENSIN I; ANIMALS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; HUMANS; PEPTIDE FRAGMENTS; RENIN-ANGIOTENSIN SYSTEM; TREATMENT OUTCOME; VASODILATION;

EID: 34249848335     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Abbas A, Gorelik G, Carbini LA, et al. 1997. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension, 30:217-21.
2. Admiraal PJ, Derkx FH, Danser AH, et al. 1990. Metabolism and production of angiotensin I in different vascular beds in subjects with hypertension. Hypertension, 15:44-55.
3. Almeida AP, Frabregas BC, Madureira MM, et al. 2000. Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Braz J Med Biol Res, 33:709-13.
4. Ambuhl P, Felix D, Khosla MC. 1994. [7-D-ALA]-angiotensin-(1-7): selective antagonism of angiotensin-(1-7) in the rat paraventricular nucleus. Brain Res Bull, 35:289-91.
5. 2 activity and sodium transport by angiotensin-(1-7). Kidney Int, 44:932-6.
6. Azizi M, Webb R, Nussberger J, et al. 2006. Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens, 24:243-56.
7. Baracho NCV, Silva ACS, Khosla M, et al. 1995. Characterization of the antidiuretic action of angiotensin-(1-7) in water-loaded rats. Hypertension, 25:1408.
8. Benter IF, Diz DI, Ferrario CM. 1993. Cardiovascular actions of angiotensin(1-7). Peptides, 14:679-84.
9. Benter IF, Diz DI, Ferrario CM. 1995a. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension, 26:1138-44.
10. Benter IF, Ferrario CM, Morris M, et al. 1995b. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. Am J Physiol, 269:H313-9.
11. Bomtempo CA, Santos GF, Santos RA, et al. 1998. Interaction of bradykinin and angiotensin-(1-7) in the central modulation of the baroreftex control of the heart rate. J Hypertens, 16:1797-804.
12. Bonner G, Preis S, Schunk U, et al. 1990. Hemodynamic effects of bradykinin on systemic and pulmonary circulation in healthy and hypertensive humans. J Cardiovasc Pharmacol, 15(Suppl 6):S46-56.
13. Bovy PR, Trapani AJ, McMahon EG, et al. 1989. A carboxy-terminus truncated analogue of angiotensin II, [Sar1]angiotensin II-(1-7)-amide, provides an entry to a new class of angiotensin II antagonists. J Med Chem, 32:520-2.
14. Brosnihan KB, Li P, Ferrario CM. 1996. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension, 27:523-8.
15. Brunner HR, Gavras H, Turini GA, et al. 1978. Long-term treatment of hypertension in man by an orally active angiotensin-converting enzyme inhibitor. Clin Sci Mol Med Suppl, 4:293s-295s.
16. Burnier M, Brunner HR. 2000. Angiotensin II receptor antagonists. Lancet 355:637-45.
17. Campagnole-Sants MJ, Diz DI, Santos RA, et al. 1989. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. Am J Physiol, 257:11324-9.
18. Campagnole-Santos MJ, Heringer SB, Batista EN, et al. 1992. Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. Am J Physiol, 263:R89-94.
19. Carey RM, Howell NL, Jin XH, et al. 2001. Angiotensin type 2 receptor-mediated hypotension in angiotensin type-1 receptor-blocked rats. Hypertension, 38:1272-7.
20. Carey RM, Siragy HM. 2003. Newly recognized components of the renin-angiotensin system: potential roles in cardiovascular and renal regulation. Endocr Rev, 24:261-71.
21. Case DB, Wallace JM, Laragh JH. 1979. Compansonbetween saralsin and converting enzyme inhibitor in hypertensive disease. Kidney Int Suppl, S107-114.
22. Cashin-Hemphill L, Holmvang G, Chan RC, et al. 1999. Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. Am J Cardiol, 83:43-7.
23. 2 receptors in the mouse heart. Hypertension, 46:937-42.
24. 2+ in mesangial cells. Eur J Pharmacol, 414:165-75.
25. Chappell M, Tallant E, Brosnihan K, et al. 1994. Conversion of angiotensin I to angiotensin-(1-7) by thimet oligopeptidase (EC 3.4.24.15) in vascular smooth muscle cells. J Vasc Med Biol, 5:129-37.
26. Chappell MC, Pirro NT, Sykes A, et al. 1998. Metabolism of angiotensin-(1-7) by angiotensin-converting enzyme. Hypertension, 31:362-7.
27. Chobanian AV, Bakris GL, Black HR, et al. 2003. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension, 42:1206-52.
28. Cipollone F, Fazia M, Iezzi A, et al. 2004. Blockade of the angiotensin II type 1 receptor stabilizes atherosclerotic plaques in humans by inhibiting prostaglandin E2-dependent matrix metalloproteinase activity. Circulation, 109:1482-8.
29. Crackower MA, Sarao R, Oudit GY, et al. 2002. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 417:822-8.
30. Cuspidi C, Ciulla M, Zanchetti A. 2006. Hypertensive myocardial fibrosis. Nephrol Dial Transplant, 21:20-3.
31. Davie AP, Mcmurray JJ. 1999. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension, 34:457-60.
32. Deddish PA, Marcic B, Jackman HL, et al. 1998. N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. Hypertension, 31:912-17.
33. Dellipizzi AM, Hilchey SD, Bell-Quilley CP. 1994. Natriuretic action of angiotensin(1-7). Br J Pharmacol, 111:1-3.
34. Dendorfer A, Dominiak P, Schunkert H. 2005. ACE inhibitors and angiotensin II receptor antagonists. Handb Exp Pharmacol, 407-42.
35. Diz DI, Pirro NT. 1992. Differential actions of angiotensin II and angiotensin-(1-7) on transmitter release. Hypertension, 19:1141-8.
36. Donoghue M, Hsieh F, Baronas E, et al. 2000. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res, 87:E1-9.
37. Faxon DP. 1995. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results ofthe MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial With Cilazapril. After Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) Study Group. J Am Coll Cardiol, 25:362-9.
38. Fernandes L, Fortes ZB, Nigro D, et al. 2001. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension, 37:703-9.
39. Ferrario CM, Averill DB, Brosmhan KB, et al. 2002a. Vasopeptidase inhibition and Ang-(1-7) in the spontaneously hypertensive rat. Kidney Int, 62:1349-57.
40. Ferrario CM, Brosnihan KB, Diz DI, et al. 1991. Angiotensin-(1-7): anew hormone of the angiotensin system. Hypertension, 18:126-33.
41. Ferrario CM, Chappell MC, Tallant EA, et al. 1997. Counterregulatory actions of angiotensin-(1-7). Hypertension, 30:535-41.
42. Ferrario CM, Jessup J, Chappell MC, et al. 2005a. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation, 111:2605-10.
43. Ferrario CM, Jessup J, Gallagher PE, et al. 2005b. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int, 68:2189-96.
44. Ferrario CM, Martell N, Yunis C, et al. 1998. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. Am J Hypertens, 11:137-46.
45. Ferrario CM, Smith RD, Brosnihan B, et al. 2002b. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. Am J Hypertens, 15:557-64.
46. Feterik K, Smith L, Katusic ZS. 2000. Angiotensin-(1-7) causes endothelium-dependent relaxation in canine middle cerebral artery. Brain Res, 873:75-82.
47. Freeman EJ, Chisolm GM, Ferrario CM, et al. 1996. Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. Hypertension, 28:104-8.
48. Gironacci MM, Valera MS, Yujnovsky I, et al. 2004. Angiotensin-(1-7) inhibitory mechanism of norepinephrine release in hypertensive rats. Hypertension, 44:783-7.
49. Hall JE. 1991. The renin-angiotensin system: renal actions and blood pressure regulation. Compr Ther, 17:8-17.
50. Handa RY, Ferrario, CM, Strandhoy JW. 1994. Angiotensin-(1-7) inhibits oxygen consumption in rat proximal tubules [abstract]. J Am Soc Nephrol, 5:659.
51. Handa RK, Ferrario CM, Strandhoy JW. 1996. Renal actions of angiotensin-(1-7): in vivo and in vitro studies. Am J Physiol, 270:F141-7.
52. Harmer D, Gilbert M, Borman R, et al. 2002. Quantitative mRNA expression profiling of ACE2, a novel homologue of angiotensin converting enzyme. FEBS Lett, 532:107-10.
53. Hayoz D. 2002. AT1 receptor antagonists: vascular protection beyond blood pressure reduction? J Hypertens, 20:2345-6.
54. Hecker M, Blaukat A, Bara AT, et al. 1997. ACE inhibitor potentiation of bradykinin-induced venoconstriction. Br J Pharmacol, 121:1475-81.
55. Heitsch H, Brovkovych S, Malinski T, et al. 2001. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension, 37:72-76.
56. Hilchey SD, Bell-Quilley CP. 1995. Association between the natriuretic action of angiotensin-(1-7) and selective stimulation of renal prostaglandin 12 release. Hypertension, 25:1238-44.
57. Igase M, Strawn WB, Gallagher PE, et al. 2005. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. Am J Physiol Heart Circ Physiol, 289:H1013-9.
58. Ishiyarna Y, Gallagher PE, Averill DB, et al. 2004. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension, 43:970-6.
59. Iyer SN, Averill DB, Chappell MC, et al. 2000. Contribution of angiotensin-(1-7) to blood pressure regulation in salt-depleted hypertensive rats. Hypertension, 36:417-22.
60. Iyer SN, Chappell MC, Averill DB, et al. 1998a. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension, 31:699-705.
61. Iyer SN, Ferrario CM, Chappell MC. 1998b. Angiotensin-(1-7) contributes to the antibypertensive effects of blockade of the renin-angiotensin system. Hypertension, 31:356-61.
62. Jaiswal N, Diz DI, Chappell MC, et al. 1992. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension, 19:1149-55.
63. Jaiswal N, Jaiswal RK, Tallant EA, et al. 1993a. Alterations in prostaglandin production in spontaneously hypertensive rat smooth muscle cells. Hypertension, 21:900-5.
64. Jaiswal N, Tallant EA, Jaiswal RK, et al. 1993b. Differential regulation of prostaglandin synthesis by angiotensin peptides in porcine aortic smooth muscle cells: subtypes of angiotensin receptors involved. J Pharmacol Exp Ther, 265:664-73.
65. Jessup J, Gallagher PE, Averill DB, et al. 2006. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic ren-2 Rats. Am J Physiol Heart Circ Physiol, 291:42166-72.
66. Johnston CI. 1995. Angiotensin receptor antagonists: focus on losartan. Lancet, 346:1403-7.
67. Langeveld B, Van Gilst WH, Tio RA, et al. 2005. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension, 45:138-41.
68. Le Tran Y, Forster C. 1997. Angiotensin-(1-7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol, 30:676-82.
69. Li P, Chappell MC, Ferrario CM, et al. 1997. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension, 29:394-400.
70. Lima CV, Paula RD, Resende FL, et al. 1997. Potentiation of the hypotensive effect of bradykinin by short-term infusion of angiotensin-(1-7) in normotensive and hypertensive rats. Hypertension, 30:542-8.
71. Machado RD, Ferreira MA, Belo AV, et al. 2002.Vasodilator effect of angiotensin-(1-7) in mature and sponge-induced neovasculature. Regul Pept, 107:05-13.
72. MacMahon S, Sharpe N, Gamble G, et al. 2000. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J Am Coll Cardiol, 36:438-43.
73. Mahon JM, Carr RD, Nicol AK, et al. 1994. Angiotensin(1-7) is an antagonist at the type 1 angiotensin II receptor. J Hypertens, 12:1377-81.
74. Maia LG, Ramos MC, Fernandes L, et al. 2004. Angiotensin-(1-7) aritagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol, 43:685-91.
75. Meng W, Busija DW 1993. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke, 24:2041-4; discussion 2045.
76. Metzger R, Bader M, Ludwig T, et al. 1995. Expression of the mouse and rat mas proto-oncogene in the brain and peripheral tissues. FEBS Lett, 357:27-32.
77. Moan A, Hoieggen A, Seljeflot I, et al. 1996. The effect of angiotensin II receptor antagonism with losartan on glucose metabolism and insulin sensitivity. J Hypertens, 14:1093-7.
78. Moritz KM, Campbell DJ, Wintour EM. 2001. Angiotensin-(1-7) in the ovine fetus. Am J Physiol Regul Integr Comp Physiol, 280:R404-9.
79. Nakao N, Yoshimura A, Morita H, et al. 2003. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet, 361:117-24.
80. Oliveira MA, Fortes ZB, Santos RA, et al. 1999. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides, 20:1195-201.
81. Osei SY, Ahima RS, Minkes RK, et al. 1993. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. Eur J Pharmacol, 234:35-42.
82. Pals DT, Masucci FD, Denning GS Jr, et al. 197 1. Role of the pressor action of angiotensin II in experimental hypertension. Circ Res, 29:673-81.
83. Paula RD, Lima CV, Khosla MC, et al. 1995. Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. Hypertension, 26:1154-9.
84. Peters S, Gotting B, Trummel M, et al. 2001. Valsartan for prevention of restenosis after stenting of type B2/C lesions: the VAL-PREST trial. J Invasive Cardioml, 13:93-7.
85. Pfeffer MA, Swedberg K, Granger CB, et al. 2003. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 362:759-66.
86. Pinheiro SV, Simoes E Silva AC, Sampaio WO, et al. 2004. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor Mas agonist in the mouse kidney. Hypertension, 44:490-6.
87. Pitt B, Segal R, Martinez FA, et al. 1997. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet, 349:747-52.
88. Porsti I, Bara AT, Busse R, et al. 1994. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol, 111:652-4.
89. Ren Y, Garvin JL, Carretero OA. 2002. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension, 39:799-802.
90. Reudelbuber TL. 2006. A place in our hearts for the lowly angiotensin 1-7 peptide? Hypertension, 47:811-15.
91. Reyes-Engel A, Morcillo L, Aranda FJ, et al. 2006. Influence of gender and genetic variability on plasma Angiotensin peptides. J Renin Angiotensin Aldosterone Syst, 7:92-7.
92. Roks AJ, Van Geel PP, Pinto YM, et al. 1999. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension, 34:296-301.
93. Sampaio WO, Nascimento AA, Santos RA. 2003. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. Am J Physiol Heart Circ Physiol, 284:H1985-94.
94. Santos RA, Brosnihan KB, Chappell MC, et al. 1988. Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension, 11:1153-7.
95. Santos RA, Brosnihan KB, Jacobsen DW, et al. 1992. Production of angiotensin-(1-7) by human vascular endothelium. Hypertension, 19:1156-61.
96. Santos RA, Campagnole-Santos MJ, Andrade SP. 2000. Angiotensin-(1-7): an update. Regul Pept, 91:45-62.
97. Santos RA, Campagnole-Santos MJ, Baracho NC, et al. 1994. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Res Bull, 35:293-8.
98. Santos RA, Simoes E Silva AC, Magaldi AJ, et al. 1996. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension, 27:875-84.
99. Santos RA, Simoes E Silva AC, Maric C, et al. 2003. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA, 100:8258-63.
100. Sasaki S, Higashi Y, Nakagawa K, et al. 2001. Effects of angiotensin-(1-7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension, 38:90-4.
101. Schiavone MT, Santos RA, Brosnihan KB, et al. 1988. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proc Natl Acad Sci USA, 85:4095-8.
102. Schindler C, Brosnihan KB, Ferrario CM, et al. 2007. Comparison of inhibitory effects of irbesartan and atorvastatin treatment on the renin angiotensin system (RAS) in veins: a randomized double-blind crossover trial in healthy subjects. J Clin Pharmacol, 47:112-20.
103. Schindler C, Schweizer J, Mueller A, et al. 2005. Candesartan treatment for peripheral occlusive arterial disease after stent angioplasty: a randomised, placebo-controlled trial. Clin Drug Invest, 25:89-97.
104. Silva LC, Fontes MA, Campagnole-Santos MJ, et al. 1993. Cardiovascular effects produced by micro-injection of angiotensin-(1-7) on vasopressor and vasodepressor sites of the ventrolateral medulla. Brain Res, 613:321-5.
105. Stergiou GS, Efstathiou SP, Skeva Ii, et al. 2002. Assessment of drug effects on blood pressure and pulse pressure using clinic, home and ambulatory measurements. J Hum Hypertens, 16:729-35.
106. Stergiou GS, Skeva Ii. 2004. Renin-angiotensin system blockade at the level of the angiotensin converting enzyme or the angiotensin type-1 receptor: similarities and differences. Curr Top Med Chem, 4:473-81.
107. Tallant EA, Ferrario CM, Gallagher PE. 2005. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol, 289:H1560-6.
108. Tallant EA, Jaiswal N, Diz DI, et al. 1991. Human astrocytes contain two distinct angiotensin receptor subtypes. Hypertension, 18:32-9.
109. Tipnis SR, Hooper NM, Hyde R, et al. 2000. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem, 275:33238-43.
110. Tom B, De Vries R, Saxena PR, et al. 2001. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade. Hypertension, 38:95-9.
111. Trachte GJ, Ferrario CM, Khosla MC. 1990. Selective blockade of angiotensin responses in the rabbit isolated vas deferens by angiotensin receptor antagonists. J Pharmacol Exp Ther, 255:929-34.
112. Ueda S, Masumori-Maemoto S, Ashino K, et al. 2000. Angiotensin-(1-7) attenuates vasoconstriction evoked by angiotensin II but not by nor-adrenaline in man. Hypertension, 35:998-1001.
113. Ueda S, Masumori-Maemoto S, Wada A, et al. 2001. Angiotensin(1-7) potentiates bradykinin-induced vasodilatation in man. J Hypertens, 19:2001-9.
114. Unger T. 2002. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol, 89:3A-9A; discussion 10A.
115. Walther T, Balschun D, Voigt JP, et al. 1998. Sustained long term potentiation and anxiety in mice lacking the Mas protooncogene. J Biol Chem, 273:11867-73.
116. Welches WR, Brosnihan KB, Ferrario CM. 1993. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolyl endopeptidase and neutral endopeptidase 24.11. Life Sci, 52:1461-80.
117. Wiemer G, Dobrucki LW, Louka FF, et al. 2002. AVE 0991, a nonpeptide mimic of the effects of angiotensin-(1-7) on the endothelium. Hypertension, 40:847-52.
118. Wilsdorf T, Gainer JV, Murphey LJ, et al. 2001. Angiotensin-(1-7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension, 37:1136-40.
119. Yoshida O, Hirayama H, Nanasato M, et al. 2005. The angiotensin II receptor blocker candesartan cilexetil reduces neointima proliferation after coronary stent implantation: a prospective randomized study under intravascular ultrasound guidance. Am Heart J, 149:e2.
120. Yusuf S, Sleight P, Pogue J, et al. 2000. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med, 342:145-53.